COVID-19 and the Biophotonics Industry

Tom Hausken

Even the biophotonics industry took a hit in 2020, although pandemic-related revenues point toward growth in 2021.


In the context of the coronavirus pandemic, the biophotonics industry can be viewed as an “essential worker.” Health care workers depend on biophotonics products to help identify and locate the coronavirus, as do the pharmaceutical companies that are rushing to develop and manufacture vaccines and cures. While the pandemic boosted sales of COVID-19–related biophotonic equipment, the crisis also interrupted the supply and demand for medical devices and services in general. In 2021, however, the sector—which sells to research institutes, hospitals, pharmaceutical companies and food-safety and environmental laboratories—is recovering well.

Log in or become a member to view the full text of this article.

This article may be available for purchase via the search at Optica Publishing Group.
Optica Members get the full text of Optics & Photonics News, plus a variety of other member benefits.

Add a Comment